Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors.

ABSTRACT:

Background

To investigate the evolution of bone metastases in patients receiving immune checkpoint inhibitors (ICI).

Methods

A single-center retrospective study included cancer patients with bone metastases treated with ICI at our institution between January 2014 and September 2019. Clinical and biological data were collected from medical records and independent expert review of imaging was performed. Target and non-target lesions were identified and followed up to 1 year. Patients were then classified as bone responder or non-responder. Comparisons between groups were performed with Student's t test or Mann-Whitney test.

Results

Among 1108 patients screened, 192 patients had bone metastases and 48 patients were included in the final analysis, with lung cancer, renal

SUBMITTER: Gefard-Gontier E 

PROVIDER: S-EPMC10991876 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature